Kornimate/medical-research-clean huggingface dataset:
development and evaluation of techniques for computer aided detection and diagnosis from existing radiologic images

Conditions: Radiology Information Systems

Summary: background: radiologic images are getting more complex. they are also being used more often. medical personnel are overwhelmed with data. computer aided detection (cad) and diagnosis may be able to improve medical care. researchers want to create and test ways to use cad. to do this, they want to use data from the clinical center s department of diagnostic radiology. objective: to create algorithms and software that accurately detect and characterize lesions, model anatomy, and monitor diseases on radiologic studies. eligibility: people of all ages who have radiologic exams stored in the clinical pacs (picture archiving system) of the clinical center since july 6, 1953 with no end date. people with target lesions of any kind will be included. design: this study will use existing data. participants will include males and females of all ages. they will be chosen by keyword search on nih databases. the data that is used may include ct, mri, ultrasound, and other images. it may include a participant s name, date of birth, and date of exam. it may include the name of the doctor, radiologist, and hospital. data such as age, gender, race, disease, and treatment may be used. other data from charts or studies may be used. imaging data of all organs of the body will be studied. data will be kept in computers and servers. the equipment will be password protected. printouts will be stored in locked rooms. this study will last 10 years.

study description: this study uses artificial intelligence techniques to improve radiology diagnosis. objective: development of computer aided detection techniques to improve radiology imaging. study population: up to 1,000,000 nih clinical center patients. description of sites/facilities conducting research: nih clinical center study duration: 10 years

Eligibility criteria:
* inclusion criteria: * all radiologic exams available in the clinical pacs (picture archiving system) of the clinical center taken from july, 6, 1953 with no end date. * males and females of all ages. * patients with target lesions of any kind will be included * patients without the target lesion will be included to determine the specificity of the computer aided detection or diagnosis algorithm exclusion criteria: none

Keywords: opportunistic screening artificial intelligence automated detection epidural masses lymphadenopathy natural history
evaluate the impact of targeted physical activity on clinically debilitated dialysis patients.

Conditions: Frailty; Pain, Chronic; Dialysis; Complications; Kidney Diseases

Summary: this research is being done to better understand the impact of the use of a specific physical activity training program (gh method) in dialysis/kidney disease patients.

the 12-month randomized trial group will include a total of 150 patients from ui health (≥ 18 years of age), who are on dialysis, or have chronic kidney disease stage 4 (ckd 4 = gfr between 15 and 29) or have chronic kidney disease stage 5 (ckd 5 = gfr below 15) and are considered clinically debilitated by their direct healthcare professional will be enrolled. randomization will be a 2:1 ratio (100 intervention, 50 control). the intervention arm will perform a 12-month exercise intervention which involves two days a week of personalized exercise rehabilitation. the control arm will receive no exercise intervention. both arms of patients will be tested on various measures of health and function both at baseline (prior to intervention) at 6 months, and at 12 months (post intervention). this study will also investigate the effects of an exercise intervention on a subgroup of pre- and post- kidney transplant patients (ppkt subgroup). this subgroup will include a total of 100 patients (≥ 18 years of age), who are on dialysis, or have ckd stage 4 or 5, and are considered clinically debilitated by their direct healthcare professional will be enrolled, or post- renal (kidney) transplant. this subgroup will perform 36 visits of exercise intervention which involves two days a week of personalized exercise rehabilitation. the investigator will also utilize validated surveys and assessment tools to assess health issue management and depression severity.

Eligibility criteria:
inclusion criteria: * clinically debilitated patients, currently on dialysis, or have ckd 4 (gfr between 15 and 29), or have ckd 5 (gfr below 15), or post- kidney transplant (for ppkt subgroup only) as stated by patient's health care professional. * adequate cognitive ability to complete the questionnaires, give consent for the study and follow the physical and diet instructions exclusion criteria: * cardiac/pulmonary disease that contraindicate the physical training * unable to give consent * unable to travel to the training center
lifestyle intervention of obese teenagers (lite) program

Conditions: Adolescent Obesity; Lifestyle Intervention

Summary: background: family-based lifestyle intervention programmes have been known to reduce overweight and improve cardiovascular risk in adolescent obesity \[1\]. this study was designed to address the gap in service provision of a family based weight management program for overweight and obese adolescents. the lite (lifestyle intervention for obese teenagers) group program is a 6-month, family-based behavioural lifestyle intervention, specifically designed to treat obesity in adolescents 10-16 years referred to the weight management clinic. the main principles underpinning lite program are that parents are identified as the agents of change responsible for implementing lifestyle change in the family . methods: the study design is a two-arm randomized controlled trial that recruited 60 overweight and obese adolescents 10-16 year olds that attended kandang kerbau women and children's hospital(kkh) weight management clinic. adolescents with secondary cause for obesity are excluded. participants are randomized to lite program with usual care or usual care. briefly, the lite program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. the key aspects covered in the lite program are in keeping with health promotion board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. the parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes. the program takes a solution focused approach with families identifying small changes that they would like to try each week instead of a child-centric approach. outcome measurement are assessed at 3 and 6 months post baseline and include anthropometric measurements, physical activity, dietary intake, metabolic profile, improvement in positive parenting behaviour and measurement of family support. primary outcome is change in body mass index (bmi) z-score at 6 months. secondary aim is to evaluate the changes in waist-height ratio and fat percentage change and improvement in positive parenting behaviour.


Eligibility criteria:
inclusion criteria: * all adolescents aged 10-16 years old who are currently enrolled in the weight management programme exclusion criteria: * intellectual disability, significant medical illness that precludes physical activity and significant psychiatric illness * secondary cause of obesity * taking of medications that can affect weight status * poor level of spoken english (adolescent/carer) * severe obesity as defined by bmi more than or equal to 40kg/m2 * sibling who is already participating in the study
urine interleukin-37 as a biomarker of mortality risk in patients with sepsis

Conditions: Sepsis

Summary: this study aims to evaluate the efficacy of il-37 as a biomarker to predict mortality risk in adults with sepsis.

sepsis patients admitted in the department of critical care medicine, zhongnan hospital will be included. there are three groups of patients in this study: control group, sepsis group and septic shock group. the interleukin-37 (il-37) concentration in urine was analyzed in the day 1, 2, 4, 6. additionally, il-37 concentration between blood stream infection groups and non-infection groups were analyzed. il-37 concentration between survivors and non-survivors were also compared. il-37 concentration were followed from day 1, 2, 4, 6.the correlation between the concentration of il-37, il-1β, il-6、il-10 and tnf-α were analyzed. furthermore, the investigators will determine the correlation between the concentration of il-37, sepsis associated organ dysfunction, 28-day mortality. lastly, the predictive value of il-37 to sepsis associated organ dysfunction and prognosis were explored.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. expected length of stay\>24 hours in intensive care unit (icu) 3. sequential organ failure assessment (sofa) score ≥ 2 on icu admission with a suspicion of infection exclusion criteria: 1. anuria 2. icu readmission in 28 days

Keywords: sepsis interleukin-37 biomarker
mln2704 in subjects with metastatic androgen-independent prostate cancer

Conditions: Prostatic Neoplasms

Summary: the purpose of the study is to determine the highest dose of mln2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. this study will also evaluate how mln2704 is taken up, broken down and eliminated by the body.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma * radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma * 18 years of age or older * progressive prostate cancer as defined by the presence of one or more of the following despite castrate levels of testosterone (testosterone \<50 ng/dl): 1. progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or x-ray and ct scan or mri) 2. progressive bone metastasis (presence of new lesion(s) on a bone scan) 3. progressive psa levels (as defined in section 3.6.1) * subjects who have received an anti-androgen must have shown progression of disease following discontinuation of the anti-androgen * subjects must remain on luteinizing hormone-releasing hormone (lhrh) analog therapy for the duration of the trial unless surgically castrate * agree to use an effective barrier method of contraception. exclusion criteria: * testosterone \>50 ng/dl * use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing * use of pc-spes within 4 weeks of dosing * prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing * use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks of dosing * prior monoclonal antibody administration, including prostascint® * peripheral neuropathy of \> grade 2, as defined by the nci common toxicity criteria for adverse events (nci ctcae) * history of cns metastasis, including incompletely treated epidural disease * history of hepatitis b or c * history of seizure disorder requiring active treatment and/or stroke * history of hiv infection * platelet count \<100,000/mm3 * absolute neutrophil count (anc) \<1,500/mm3 * hematocrit \<27 percent * abnormal coagulation profile (elevated pt, and/or inr, ptt) * serum creatinine \>2.0 mg/dl, or creatinine clearance \ 2.0 mg/dl * ast or alt \>1.5 x uln * bilirubin (total) \>1.25 x uln * serum calcium \>12.5 mg/dl * active serious infection not controlled by antibiotics * active angina pectoris or ny heart association class iii-iv heart disease * karnofsky performance status \<60% * life expectancy \<6 months * other serious illness(es) involving the cardiac, respiratory, cns, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd)

Conditions: Temporomandibular Joint Disorders

Summary: the purpose of this study is to determine whether the combination of cognitive-behavioral treatment and nortriptyline are more effective than each treatment alone in reducing the pain and disability associated with tmd.

this is a randomized, controlled trial evaluating pharmacological (nortriptyline vs. active placebo - benztropine) and psychological (cognitive-behavioral therapy vs. disease education) treatments for pain and disability due to temporomandibular joint disorder (tmd). patients 18 to 65 years old meeting rdc criteria for tmd and other eligibility criteria complete a 3-week baseline monitoring phase prior to randomization. active treatment consists of weekly visits for 8 week, then maintenance treatment for 6 months. outcome measures include pain, physical and psychosocial function and are assessed at post-treatment, 3-months, and 6-months

Eligibility criteria:
inclusion: * age \>= 18 and \<= 65 * pain \>= 3 months duration due to temporomandibular joint disorder * pain due to tmd is primary if other pain conditions present exclusion: * continuous, chronic painful non-reducing disc displacement of tmj and patient can't open mouth * unstable or acute severe pain from another pain condition * patient is pregnant * presence of a medical condition that contraindicates nortriptyline: angle-closure glaucoma,symptomatic orthosis * ekg: first degree heart block or qtc \> 450 msec * unstable angina or a history of a myocardial infarction within the past 3 months * current treatment with an antidepressant which cannot be withdrawn * current use of a medication that interacts with nortriptyline to raise blood levels, such as selective serotonin reuptake inhibitors (e.g.,paroxetine), systemic anti-fungal agents (fluconazole), antiarrhythmics (e.g., quinidine), antipsychotics (e.g., haloperidol), and antibiotics (e.g., erythromycin). * presence of dementia, psychosis or other disorder of cognition that impairs ability to participate in minimal contact intervention * beck depression inventory (bdi) score \>= 35 or bdi item #9 (suicide item) is scored \> 1 * patient has a terminal illness with a life expectancy of less than six months * history of arthrotomy of temporomandibular joint * history of allergic reaction to nortriptyline or benztropine * history of a therapeutic trial with nortriptyline (dose \>= 100 mg for at least 3 weeks)
percutaneous versus endoscopic ultrasound-guided liver biopsy (pereus)

Conditions: Liver Diseases

Summary: although the use of liver biopsy (lb) has decreased with the emerging non-invasive markers and techniques to evaluate liver fibrosis, histopathologic examination of liver tissue is necessary to confirm the type of liver injury. the aim of our study is to compare two methods for obtaining histological material from the liver: the percutaneous liver biopsy (plb) and the endoscopic ultrasound (eus) guided liver biopsy (eus-lb)

lb remains the gold standard diagnostic test for most of the focal and parenchymal liver diseases. lb has an important diagnostic role in selected parenchymal liver diseases such as autoimmune hepatitis and infiltrative liver disorders, and in some cases, it helps clinicians to elucidate between overlapping diagnoses traditionally, percutaneous (plb) or transjugular approaches have been used to acquire liver samples. in recent tears eus has emerged as an alternative and safe method to obtain liver samples, by puncturing the liver from the gastric or duodenal wall. in fact, eus-guided lb has been shown equal or superior compared to plb and transjugular approaches in retrospective series. eus - lb has shown to produce excellent histological performance based on liver society guidelines requirements for parameters used in assessing histological yield which include the number of complete portal triads (cpt), sample size and total specimen length (tsl) with a low rate of adverse events eus - lb has several advantages over the traditional liver biopsy methods: it provides simultaneous access to both liver lobes, enables real-time visualization avoiding the puncture of a large vessel and then reducing the rate of complications, it allows to perform a simultaneously endoscopic and endosonography evaluation of the pancreatobiliary system and it could decrease the level of the anxiety of patients (by the use of deep sedation) and then perhaps increasing the satisfaction with the procedure despite the fact of the high diagnostic yield of eus-lb in obtaining adequate samples from the liver and the low rate of adverse events reported with this method, there is an almost complete lack of randomized trials comparing eus - lb with the traditional percutaneous route. the aim of our study is to compare the quality of samples obtained and the diagnostic efficacy of eus - lb against plb in all patients that have an indication for a liver biopsy

Eligibility criteria:
patients for whom a liver biopsy have been indicated. inclusion criteria: * age over 18 years, any gender * understanding and informed consent signed * fit for deep sedation exclusion criteria: * age below 18 years * not signed informed consent * contraindication for a deep sedation * pregnancy * focal liver lesion that requires biopsy visualized by other imaging techniques * coagulopathy (inr\>1.5 or platelets \< 50,000) * inability to withdraw anticoagulant or antithrombotic agents

Keywords: biopsy histology endoscopic ultrasound diagnosis
a study of nivolumab and relatlimab in combination with bevacizumab in advanced liver cancer

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (hcc).


Eligibility criteria:
inclusion criteria: * histologically confirmed advanced/metastatic hepatocellular carcinoma (hcc) * naïve to systemic therapy for advanced/metastatic hcc (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with bms medical team) * child-pugh score of 5 or 6 (ie, child-pugh a) * eastern cooperative oncology group (ecog) performance status 0 or 1 exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc or mixed cholangiocarcinoma and hcc * prior allogenic stem cell or solid organ transplantation * untreated symptomatic central nervous system (cns) metastases * clinically significant ascites as defined by: i) prior ascites that required treatment and requires on-going prophylaxis, or ii) current ascites requiring treatment other protocol-defined inclusion/exclusion criteria apply

Keywords: hepatocellular carcinoma hcc liver cancer relatlimab nivolumab bevacizumab first line hcc
transcervical radiofrequency ablation of uterine fibroids global registry

Conditions: Uterine Fibroid

Summary: sage is an observational post market registry with the objective of characterizing long term outcomes after treatment of uterine fibroids with the sonata system in real world clinical practice settings.

patients whom have selected the ce-marked sonata system for treatment of fibroids will be approached for study participation. participation in the trial will consist of data collection in the form of questionnaires prior to and after the treatment at the following intervals: pre-procedure, 4 weeks, 1, 2, 3, 4 and 5 years following treatment. the following data points will be collected: length of stay, time to return to normal activities (treatment recovery questionnaire), time to return to sexual activity (treatment recovery questionnaire), change in fibroid symptom severity and quality of life (ufs-qol), change in general health outcome (eq-5d), work productivity and activity impairment (wpai), subject satisfaction and overall treatment effect (overall treatment effect and satisfaction questionnaire), pregnancy occurrence and outcome, non-medical re-intervention, adverse events related to the device/procedure. validated questionnaires are used where appropriate (ufs-qol, e1-5d and wpai). double data entry will occur to ensure accurate capture of subject reported data. monitoring will occur throughout the course of the trial to ensure adherence to the protocol. as an observational trial, there are no pre-specified statistically powered endpoints.

Eligibility criteria:
inclusion criteria: * have selected sonata for treatment of symptomatic uterine fibroids or is participating in the open study (evaluation of uterine patency following sonography-guided transcervical ablation of fibroids, nct02844920, protocol # cl04897) or has completed participation in the open study within the last 14 months * speaks and reads a language for which questionnaires are available * are greater than or equal to 18 years of age at the time of enrollment * willing and able to read, understand and sign the informed consent form, to participate in the registry and to adhere to all registry study follow-up requirements exclusion criteria: * any reason for which, in the opinion of the investigator, the individual study patient is not appropriate or suitable for participation in the registry

Keywords: radiofrequency ablation